Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection

Authors: Takahiro Morita, Hiroaki Kurihara, Kenta Hiroi, Natsuki Honda, Hiroshi Igaki, Jun Hatazawa, Yasuaki Arai, Jun Itami

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

We evaluated dynamic changes in 18F–borono-L-phenylalanine (18F–BPA) uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck (SCC) and malignant melanoma (MM) during boron neutron capture therapy (BNCT) patient selection.

Methods

Dynamic changes in the maximum standardized uptake value (SUVmax), tumor-to-normal tissue ratio (TNR), and tumor-to-blood pool ratio (TBR) for 18F–BPA were evaluated in 20 patients with SCC and 8 patients with MM.

Results

SUVmax in SCC tumors decreased significantly from 30 to 120 min. There was a non-statistically significant decrease in SUVmax for SCC tumors from 30 to 60 min and from 60 to 120 min. Patients with MM had nonsignificant SUVmax changes in 18F–BPA uptake on delayed imaging. Nonsignificant 18F–BPA TNR and TBR changes were seen in patients with SCC and MM.

Conclusions

Dynamic changes in SUVmax for 18F–BPA uptake had a washout pattern in SCC and a persistent pattern in MM. Dynamic 18F–BPA -PET studies should be performed to investigate the pharmacokinetics of 18F–BPA in humans and select appropriate candidates who may benefit from BNCT.
Literature
1.
Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzen L, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 2008;88:183-191.
2.
Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol. 2014;9:6.CrossRefPubMedPubMedCentral
3.
Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55:146–53.CrossRefPubMed
4.
Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet. 1989;2:388–9.CrossRefPubMed
5.
Barth RF, Vicente MG, Harling OK, Kiger WS 3rd, Riley KJ, Binns PJ, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7:146.CrossRefPubMedPubMedCentral
6.
Herrera MS, Gonzalez SJ, Minsky DM, Kreiner AJ. Evaluation of performance of an accelerator-based BNCT facility for the treatment of different tumor targets. Phys Med. 2013;29:436–46.CrossRefPubMed
7.
Tani H, Kurihara H, Hiroi K, Honda N, Yoshimoto M, Kono Y, et al. Correlation of (18)F-BPA and (18)F-FDG uptake in head and neck cancers. Radiother Oncol. 2014;113:193–7.CrossRefPubMed
8.
Futamura G, Kawabata S, Siba H, Kuroiwa T, Suzuki M, Kondo N, et al. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. Radiat Oncol. 2014;9:237.CrossRefPubMedPubMedCentral
9.
Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998;39:325–33.PubMed
10.
Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998;4:1833–41.PubMed
11.
Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 2004;61:1069–73.CrossRefPubMed
12.
Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009;67:S348–50.CrossRefPubMed
13.
Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot. 2009;67:S37–42.CrossRefPubMed
14.
Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.CrossRefPubMedPubMedCentral
15.
Liberman SJ, Dagrosa A, Jiménez Rebagliati RA, Bonomi MR, Roth BM, Turjanski L, et al. Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl Radiat Isot. 2004;61:1095–100.CrossRefPubMed
16.
Fukuda H, Honda C, Wadabayashi N, Kobayashi T, Yoshino K, Hiratsuka J, et al. Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Melanoma Res. 1999;9:75–83.CrossRefPubMed
17.
Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum A. 1991;42:325–8.CrossRefPubMed
18.
Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, et al. Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol. 2013;40:625–9.CrossRefPubMed
19.
Stevens BR. Vertebrate intestine apical membrane mechanisms of organic nutrient transport. Am J Phys. 1992;263:R458–63.
20.
Detta A, Cruickshank GS. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009;69:2126–32.CrossRefPubMed
21.
Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254–66.CrossRefPubMed
22.
Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J. Type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med. 2007;48:2063–71.CrossRefPubMed
23.
Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human Ltype amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302.CrossRefPubMed
24.
Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 2013;13:482.CrossRefPubMedPubMedCentral
25.
Slominski A, Zmijewski MA, Pawelek J. Tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2012;25:14–27.CrossRefPubMed
26.
Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Liu YW, et al. BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor. Appl Radiat Isot. 2011;69:1803–6.CrossRefPubMed
27.
Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, et al. First clinical case of boron neutron capture therapy for head and malignancies using 18F-BPA PET. Head Neck. 2006;28:850–5.CrossRefPubMed
28.
Ariyoshi Y, Shimahara M, Kimura Y, Ito Y, Shimahara T, Miyatake S, et al. Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions. Oncol Lett. 2011;2:423–7.CrossRefPubMedPubMedCentral
29.
Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med. 1997;38:1762–7.PubMed
30.
Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.CrossRefPubMed
31.
Kobayashi K, Kurihara H, Watanabe Y, Murakami N, Inaba K, Nakamura S, et al. Vivo spatial correlation between (18)F-BPA and (18)F-FDG uptakes in head and neck cancer. Appl Radiat Isot. 2016;115:138–46.CrossRefPubMed
Metadata
Title
Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection
Authors
Takahiro Morita
Hiroaki Kurihara
Kenta Hiroi
Natsuki Honda
Hiroshi Igaki
Jun Hatazawa
Yasuaki Arai
Jun Itami
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0949-y

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue

Research

Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance

Research

Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals

Research

Re-irradiation in lung disease by SBRT: a retrospective, single institutional study

Research

Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation

Research

Worth a local treatment? – Analysis of modern radiotherapy concepts for oligometastatic prostate cancer

Research

Hyperfractionated abdominal reirradiation for gastrointestinal malignancies